BRIDGE CAR Trademark

Trademark Overview


On Tuesday, December 13, 2022, a trademark application was filed for BRIDGE CAR with the United States Patent and Trademark Office. The USPTO has given the BRIDGE CAR trademark a serial number of 79368443. The federal status of this trademark filing is REGISTERED as of Tuesday, June 18, 2024. This trademark is owned by Biosceptre (Aust) Pty Ltd. The BRIDGE CAR trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Biopharmaceutical and pharmaceutical preparations for treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; veterinary preparations, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, ps...

Analysis of biological samples; biopharmaceutical and pharmaceutical development and research and evaluation services in the field of cell based therapeutics and gene therapy for the treatment of disease, injuries and disorders; biotechnology laboratory services; medical and scientific laboratory services; scientific, medical and clinical research consultation services and scientific, medical and clinical research and development services, including in the field of hematology, immunology, cancer research, developmental biology and life sciences, biotechnology, medical technology, cell culture, tissue engineering, genetic engineering, regenerative medicine, immunotherapy and immunomodulation; medical and scientific research, namely, conducting pre-clinical and clinical trials for others; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and...
bridge car

General Information


Serial Number79368443
Word MarkBRIDGE CAR
Filing DateTuesday, December 13, 2022
Status700 - REGISTERED
Status DateTuesday, June 18, 2024
Registration Number7416502
Registration DateTuesday, June 18, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 2, 2024

Trademark Statements


Goods and ServicesBiopharmaceutical and pharmaceutical preparations for treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; veterinary preparations, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; veterinary preparations, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; biological preparations for veterinary purposes, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; biological preparations for veterinary purposes, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; cultures of microorganisms for medical and veterinary use; biological preparations for medical purposes, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; biological preparations for medical purposes, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; drugs for medical purposes, namely biopharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; drugs for medical purposes, namely pharmaceutical preparations for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; diagnostic preparations for medical purposes; enzymes for medical purposes; biochemical medicines for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; vaccines; bioengineering pharmaceutical solutions for use in expanding cells for therapeutic use to patients with blood cancers and other diseases; biopharmaceuticals, namely biopharmaceutical products for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; cells and biological preparations, namely, blood, stem cells, adult blood cells, immune cells, immunomodulatory cells, umbilical cord cells, umbilical cord blood, and placental tissue intended for medical and clinical use, including, blood, stem cells, adult blood cells, immune cells, immunomodulatory cells, umbilical cord cells, umbilical cord blood, and placental tissue; bioengineered cells for use in immunotherapies; diagnostic substances and diagnostic preparations for medical purposes; gene and cell therapy and prophylaxis products, namely, therapeutic pharmaceuticals for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; gene and cell therapy prophylaxis vector preparations for therapeutic purposes for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; pharmaceutical preparations and products, namely pharmaceutical preparations and products for use in the treatment of autoimmune diseases, cancer, tumors, blood-related diseases, inflammation, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, and respiratory diseases and disorders; pharmaceutical preparations in the nature of cell solutions to enable cell expansion for therapeutic purposes; reagents for ex vivo cell processing in particular media suitable for the expansion of cells for therapeutic purposes; cell products for therapeutic purposes, namely stem and progenitor cell, adult cell, immune cell, cell therapy and gene therapy products; cells for medical purposes
Goods and ServicesAnalysis of biological samples; biopharmaceutical and pharmaceutical development and research and evaluation services in the field of cell based therapeutics and gene therapy for the treatment of disease, injuries and disorders; biotechnology laboratory services; medical and scientific laboratory services; scientific, medical and clinical research consultation services and scientific, medical and clinical research and development services, including in the field of hematology, immunology, cancer research, developmental biology and life sciences, biotechnology, medical technology, cell culture, tissue engineering, genetic engineering, regenerative medicine, immunotherapy and immunomodulation; medical and scientific research, namely, conducting pre-clinical and clinical trials for others; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceutical preparations and substances for use in clinical trials; chemical analysis; industrial design; conducting technical project studies in the fields of medicine, biotechnology, therapeutics, pharmaceuticals, biopharmaceuticals, biotherapeutics, radiology, cardiology, oncology, epidemiology, pulmonology, neurology, hematology, endocrinology, otolaryngology, gastroenterology, nephrology, gynecology, obstetrics, urology, orthopedics, ophthalmology, pathology, pediatrics, surgery, medical genetics, medical genomics, dermatology, immunology, and preventive medicine; research and development of new products for others; material testing; biological research; scientific laboratory services; scientific research; bacteriological research

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 28, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, April 28, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBiosceptre (Aust) Pty Ltd
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressAU

Party NameBiosceptre (Aust) Pty Ltd
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressAU

Party NameBiosceptre (Aust) Pty Ltd
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressAU

Trademark Events


Event DateEvent Description
Monday, September 18, 2023ASSIGNED TO EXAMINER
Thursday, April 27, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, April 28, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 2, 2023APPLICATION FILING RECEIPT MAILED
Monday, September 18, 2023NON-FINAL ACTION WRITTEN
Tuesday, September 19, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Saturday, September 30, 2023REFUSAL PROCESSED BY MPU
Saturday, September 30, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, October 25, 2023REFUSAL PROCESSED BY IB
Thursday, February 8, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 8, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 8, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 28, 2024EXAMINERS AMENDMENT -WRITTEN
Wednesday, February 28, 2024EXAMINERS AMENDMENT E-MAILED
Wednesday, February 28, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, February 28, 2024EXAMINER'S AMENDMENT ENTERED
Thursday, February 29, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 13, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 27, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 27, 2024NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, April 2, 2024PUBLISHED FOR OPPOSITION
Tuesday, April 2, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 16, 2024NOTIFICATION PROCESSED BY IB
Tuesday, June 18, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, June 18, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED